Vaccitech Newsroom

Newsroom

News & updates

Update: INVICTUS Study

Vaccitech has taken the decision not to proceed with season 2 of the current FLU007 (Invictus) study due to the changes recommended by the UK Government which directed the NHS to use FLUAD (adjuvanted TIV) vaccine in the 65 year old and over population in the 2018/19...

New UK-China biotech collaboration to develop shingles vaccine

Vaccitech will combine Oxford University vaccine know-how with the manufacturing expertise of China’s CanSino Biologics in collaboration focused on herpes zoster. Vaccitech Limited, a UK-based company developing products to treat and prevent multiple infectious...

Universal Flu Vaccine Data Presented at NFID 2018

Data on safety and immunogenicity of Vaccitech’s flu vaccine have been presented at the 2018 Annual Conference on Vaccinology Research, run by the National Foundation for Infectious Diseases. The presentation was entitled: A Clinical Study to Determine the Safety and...

Flu vaccine Study Recruits First Participants

The world’s first NHS trial for a universal flu vaccine has recruited its first round of participants, with over 862 people signing up to take part since the trial launched in October 2017. This marks the end of the first phase of the trial, which will open again for...